Home » Companies » London Stock Exchange » Scancell Holdings

Scancell Holdings

LON:SCLP: Stock Share Price & Live Data

7.79 GBX
+0.03 (0.45%)
2020-01-22 16:30:00 GMT
Price open 7.83
Close yesterday 7.75
Market cap 36.23M
Volume 333.69K
Day high 7.98
Day low 7.46
Year high 10.00
Year low 3.50

About Scancell Holdings

Founded in 1997, Scancell Plc is in the biopharmaceutical industry working on developing and discovering antibodies of monoclonal nature and relevant vaccines for cancer treatment. With its headquarters in Oxford, United Kingdom the company’s shares trade on the London Stock Exchange.

Cancer naturally occurs when numerous fast-growing cancer cells cannot be contained and controlled by the body’s natural defense system. In the process of the growth spurt, they overtake the body’s natural system and develop into tumors. To counter this, Scancell develops immunotherapies that play the role of stimulating the body’s immune system to enable it to fight or prevent cancer. These are AvidiMab, an antibody, which is an anti-glycan and vaccines (Moditope and ImmunoBody). All of which are technologies developed for the attack and destruction of cancer cells. They do this by stimulating the immune system of the patient to actively respond to the developing tumor by rejecting it or destroying it altogether.

Latest Scancell Holdings News

Scancell share price surges on encouraging results from cancer drug trial

Nottingham-based biotech firm may seek financing from pharma giants for further trials

Overview

Name
Scancell Holdings Plc
Exchange
London Stock Exchange
Last trade time
2020-01-22 16:30:00
Earnings per share
-0.01
Price/earnings
N/A

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.